Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

被引：10

作者：

Lacina, Piotr ^{[1
]}

Butrym, Aleksandra ^{[2
]}

Frontkiewicz, Diana ^{[3
]}

Mazur, Grzegorz ^{[4
]}

Bogunia-Kubik, Katarzyna ^{[1
]}

机构：

[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Lab Clin Immunogenet & Pharmacogenet, PL-53114 Wroclaw, Poland

[2] Wroclaw Med Univ, Dept Canc Prevent & Therapy, PL-50556 Wroclaw, Poland

[3] Sokolowski Specialist Hosp, Dept Haematol, PL-58309 Walbrzych, Poland

[4] Wroclaw Med Univ, Dept Internal Occupat Dis Hypertens & Clin Oncol, PL-50556 Wroclaw, Poland

来源：

CURRENT ISSUES IN MOLECULAR BIOLOGY | 2022年 / 44卷 / 01期

关键词：

BSG; basigin; CD147; MM; multiple myeloma; survival; MATRIX-METALLOPROTEINASE INDUCER; IMMUNOGLOBULIN SUPERFAMILY; GROWTH-FACTOR; UP-REGULATION; EMMPRIN; EXPRESSION; CANCER; BIOMARKER; GENE; BASIGIN/CD147;

D O I：

10.3390/cimb44010026

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

CD147 (basigin, BSG) is a membrane-bound glycoprotein involved in energy metabolism that plays a role in cancer cell survival. Its soluble form is a promising marker of some diseases, but it is otherwise poorly studied. CD147 is overexpressed in multiple myeloma (MM) and is known to affect MM progression, while its genetic variants are associated with MM survival. In the present study, we aimed to assess serum soluble CD147 (sCD147) expression as a potential marker in MM. We found that sCD147 level was higher in MM patients compared to healthy individuals. It was also higher in patients with more advanced disease (ISS III) compared to both patients with less advanced MM and healthy individuals, while its level was observed to drop after positive response to treatment. Patients with high sCD147 were characterized by worse overall survival. sCD147 level did not directly correlate with bone marrow CD147 mRNA expression. In conclusion, this study suggests that serum sCD147 may be a prognostic marker in MM.

引用

页码：350 / 359

页数：10

共 48 条

[1] Identification of ADAM12 as a Novel Basigin Sheddase [J].

Albrechtsen, Reidar ;

Albrechtsen, Nicolai J. Wewer ;

Gnosa, Sebastian ;

Schwarz, Jeanette ;

Dyrskjot, Lars ;

Kveiborg, Marie .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)

[2] Interleukin-17A enhances the production of CD147/extracellular matrix metalloproteinase inducer by monocytes from patients with psoriasis [J].

Amezcua-Guerra, L. M. ;

Ortega-Springall, M. F. ;

Guerrero-Ponce, A. E. ;

Vega-Memije, M. E. ;

Springall, R. .

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (20) :10601-10604

[3] VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level [J].

Arcondeguy, Tania ;

Lacazette, Eric ;

Millevoi, Stefania ;

Prats, Herve ;

Touriol, Christian .

NUCLEIC ACIDS RESEARCH, 2013, 41 (17) :7997-8010

[4] Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation [J].

Arendt, B. K. ;

Walters, D. K. ;

Wu, X. ;

Tschumper, R. C. ;

Huddleston, P. M. ;

Henderson, K. J. ;

Dispenzieri, A. ;

Jelinek, D. F. .

LEUKEMIA, 2012, 26 (10) :2286-2296

[5] Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation [J].

Arendt, Bonnie K. ;

Walters, Denise K. ;

Wu, Xiaosheng ;

Tschumper, Renee C. ;

Jelinek, Diane F. .

ONCOTARGET, 2014, 5 (14) :5686-5699

[6] IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma [J].

Bolomsky, Arnold ;

Huebl, Wolfgang ;

Spada, Stefano ;

Muelduer, Ercan ;

Schlangen, Karin ;

Heintel, Daniel ;

Rocci, Alberto ;

Weissmann, Adalbert ;

Fritz, Veronique ;

Willheim, Martin ;

Zojer, Niklas ;

Palumbo, Antonio ;

Ludwig, Heinz .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (03) :269-278

[7] Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells [J].

Egawa, Nagayasu ;

Koshikawa, Naohiko ;

Tomari, Taizo ;

Nabeshima, Kazuki ;

Isobe, Toshiaki ;

Seiki, Motoharu .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (49) :37576-37585

[8] Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity [J].

Eichner, Ruth ;

Heider, Michael ;

Fernandez-Saiz, Vanesa ;

van Bebber, Frauke ;

Garz, Anne-Kathrin ;

Lemeer, Simone ;

Rudelius, Martina ;

Targosz, Bianca-Sabrina ;

Jacobs, Laura ;

Knorn, Anna-Maria ;

Slawska, Jolanta ;

Platzbecker, Uwe ;

Germing, Ulrich ;

Langer, Christian ;

Knop, Stefan ;

Einsele, Herrmann ;

Peschel, Christian ;

Haass, Christian ;

Keller, Ulrich ;

Schmid, Bettina ;

Goetze, Katharina S. ;

Kuster, Bernhard ;

Bassermann, Florian .

NATURE MEDICINE, 2016, 22 (07) :735-743

[9] CD147 promotes epithelial-mesenchymal transition of prostate cancer cells via the Wnt/β-catenin pathway [J].

Fang, Fang ;

Li, Qiang ;

Wu, Mingyue ;

Nie, Chunhua ;

Xu, Haiyue ;

Wang, Liguo .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (04) :3154-3160

[10] Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status [J].

Granja, Sara ;

Marchiq, Ibtissam ;

Le Floch, Renaud ;

Moura, Conceicao Souto ;

Baltazar, Fatima ;

Pouyssegur, Jacques .

ONCOTARGET, 2015, 6 (09) :6708-6721

← 1 2 3 4 5 →